OTC · TXTM
ProText Mobility, Inc.
$0.01+$0.00 (+0.82%)
ProText Mobility, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.86% below the high.
Loading market information…
OTC · SRNE · USD
Stock price, earnings
Quote as of Oct 30, 2026, 03:45 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
Sorrento Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 98.12% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
Sorrento Therapeutics, Inc.’s next earnings report is currently expected on Nov 6, 2026, with estimated earnings per share of $0.42. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow Sorrento Therapeutics, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
Sorrento Therapeutics, Inc. is a biopharmaceutical company, active in both clinical development and commercial operations, dedicated to creating treatments for a range of serious conditions including cancer, autoimmune disorders, inflammatory diseases, viral infections, and neurodegenerative ailments. The company's operations are divided into two distinct segments: Sorrento Therapeutics and Scilex. A core focus lies in cancer therapeutics, where Sorrento harnesses its proprietary G-MAB antibody library. This is complemented by advanced, targeted delivery systems such as chimeric antigen receptor T-cell therapy (CAR-T), dimeric antigen receptor T-cell therapy, antibody-drug conjugates, and innovative bispecific antibody approaches. Additionally, their Sofusa drug delivery technology offers a unique method for introducing biologics directly into the lymphatic system. Sorrento's clinical pipeline features several promising candidates. These include an anti-CD38 CAR-T therapy currently being developed for multiple myeloma, amyloidosis, and graft-versus-host disease. They are also advancing resiniferatoxin, a non-opioid-based TRPV1 agonist neurotoxin, for managing late-stage cancer pain and osteoarthritis knee pain. Furthermore, ZTlido, a lidocaine delivery system, addresses postherpetic neuralgia. Other significant developments comprise SEMDEXA, an injectable viscous gel in Phase III trials for sciatica, a specific form of low back pain; SP-103, an investigational non-aqueous lidocaine topical system targeting chronic low back pain; and SP-104, a novel low-dose delayed-release naltrexone hydrochloride formulation for fibromyalgia treatment. The company actively engages in strategic collaborations, including partnerships with SmartPharm Therapeutics Inc. to develop a gene-encoded antibody vaccine against COVID-19, and with Celularity, Inc. for a Phase I/II clinical study involving up to 94 COVID-19 patients. Sorrento also works with the Mount Sinai Health System on COVI-SHIELD, an antibody therapy designed to combat SARS-CoV-2 infection, and with the Mayo Clinic on a Phase Ib pilot study utilizing the Sofusa lymphatic drug delivery technology for Ipilimumab in melanoma patients. Established in 2006, Sorrento Therapeutics, Inc. is headquartered in San Diego, California.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 06:49 PM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q1 2022 | May 5, 2022 | -$0.12+52.0% vs estimate | $18.39M-6.93% vs estimate |
|---|
| Q4 2021 | Mar 11, 2022 | -$0.47-62.07% vs estimate | $13.08M+0.58% vs estimate |
|---|
| Q3 2021 | Nov 5, 2021 | -$0.40-90.48% vs estimate | $12.06M+25.7% vs estimate |
|---|
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
THE ANALYST VIEW
15 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
KEEP COMPARING
$0.01+$0.00 (+0.82%)
ProText Mobility, Inc.’s quoted price sits in the upper half of its reported 52-week range, 42.86% below the high.
$4.71+$0.06 (+1.29%)
Viskase Companies, Inc.’s quoted price sits in the lower half of its reported 52-week range, 86.06% below the high.
$0.42-$0.02 (-4.09%)
Ensysce Biosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 81.16% below the high.
CA$0.04CA$0.00 (0.0%)
Kane Biotech Inc.’s quoted price sits in the upper half of its reported 52-week range, 30.0% below the high.
€1.88-€0.23 (-10.9%)
Rapid Nutrition PLC’s quoted price sits in the lower half of its reported 52-week range, 87.47% below the high.
£0.00-£0.00 (-7.41%)
Futura Medical plc’s quoted price sits in the lower half of its reported 52-week range, 93.75% below the high.
$0.01$0.00 (0.0%)
MYND Life Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 88.0% below the high.
CA$0.09-CA$0.02 (-15.0%)
Doseology Sciences Inc.’s quoted price sits in the lower half of its reported 52-week range, 91.5% below the high.
